Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRAY-ZONE: Aspirin and Atorvastatin in Non-ACS Patients with Elevated Troponin
NCT03820466Phase 3Terminated
- Start
- Feb 2020
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aspirin and atorvastatin in cardiovascular diseases (CVD) (4 arms). Primary endpoint: Myocardial infarction, cardiovascular death, and/or revascularization at 12 months. Started Feb 2020; status: terminated.
02
Drugs
aspirinatorvastatin
03
Conditions
cardiovascular diseases (CVD)
Beyond the preview
Go deeper on NCT03820466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03820466.